When CDMO Lonza shelled out $5.5 billion for capsule-maker Capsugel in 2017, it made a big bet the booming capsule market would drive revenue. Now, with demand continuing to grow, Lonza is putting another down payment on capsules to keep up.
Lonza will spend $93 million to expand its capsule manufacturing by 15% across eight sites globally in a move to add more than 30 billion doses per year to its capacity, the Swiss manufacturer said Thursday.
The company’s expansion of its Capsugel technology manufacturing comes amid booming demand for capsules in the pharmaceutical and nutritional health fields, Lonza said. Back in 2019, Lonza bumped up capacity in its Capsules and Health Ingredients (CHI) unit, which includes the Capsugel portfolio, by 10% to keep up with demand.
Lonza’s newest investment will be doled out to eight sites including: Bornem, Belgium; Colmar, France; Greenwood, Indiana; Haryana, India; Jakarta, Indonesia; Puebla, Mexico; Sagamihara, Japan; and Suzhou, China.
The company’s capsule growth will allow Lonza to focus on next-gen dosage forms in its CHI unit, which includes lipid multiparticulates and several time-release dosages currently in the research phase, Lonza said.